Roth Capital Downgrades Ligand Pharma (LGND) to Neutral Citing Valuation
Tweet Send to a Friend
Roth Capital downgraded Ligand Pharma (NASDAQ: LGND) from Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
